VTX 805
Alternative Names: VTX-805Latest Information Update: 28 Jul 2024
At a glance
- Originator Vivet Therapeutics
- Developer CIMA- Universidad de Navarra; Vivet Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Liver disorders
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Liver-disorders in France (Parenteral)
- 28 Jul 2024 No recent reports of development identified for preclinical development in Liver-disorders in Spain (Parenteral)
- 16 Jun 2020 Preclinical trials in Liver disorders in France (Parenteral), prior to June 2020 (Vivet Therapeutics pipeline, June 2020)